#United States #Stamford #Opioid Crisis #Knoa Pharma #Michael Goettler

Knoa Pharma Welcomes Michael Goettler as CEO

Knoa Pharma, a pharmaceutical company with a clear mission to combat the opioid crisis, has appointed Michael Goettler as President and Chief Executive Officer, effective July 6, 2026. This leadership change comes as the company seeks to strengthen its commitment to public health by ensuring the safe distribution of opioid medications and improving access to essential treatments for opioid use disorder.

Michael Goettler brings over three decades of invaluable experience to this role, having previously served as CEO of Viatris, a multinational healthcare company. His extensive background includes leadership positions at renowned firms such as Sanofi and Pfizer, where he oversaw operations in various areas including research and development, medical affairs, and global markets. His proven capability in steering organizations aligns perfectly with Knoa Pharma's goal of promoting responsible medication distribution and innovative healthcare solutions.

In a statement, Dr. Norbert Riedel, Chairman of the Board at Knoa Pharma, expressed confidence in Goettler’s leadership abilities, highlighting his commitment to excellence and his readiness to advance the company's mission. Goettler himself expressed his deep respect for the company's purpose, emphasizing that his ambition to create a positive impact on public health is in tandem with Knoa Pharma’s mission to mitigate the opioid crisis.

Knoa Pharma was established with a fundamental public health aim: to develop effective strategies to confront the opioid epidemic. The newly appointed CEO is set to work closely with a dedicated team that is passionate about making a significant difference in the lives of patients and communities affected by substance use disorders. Goettler's appointment signals a renewed focus on the company's vision to distribute opioid analgesics responsibly while also expanding access to overdose reversal medications and affordable treatments.

Under Goettler's leadership, Knoa Pharma aims to build a sustainable business model that not only meets the needs of patients but also respects community values and safety through safe medicine distribution practices. His vision aligns with the organization's commitment to pharmaceutical ethics, asserting that companies have a responsibility to foster goodwill, particularly in healthcare.

The company has initiated various programs designed to enhance patient care and support recovery from addiction. These initiatives underscore Knoa Pharma's status as a non-profit organization where every aspect of its operation is directed towards enhancing public health outcomes, saving lives, and ensuring that patients can access critical recovery resources. Additionally, Goettler will hold a seat as the fifth member of the Knoa Pharma Board, allowing him further influence over organizational decisions and strategy.

Michael Goettler earned his MBA from the University of Texas at Austin and obtained a graduate degree from the Koblenz School of Corporate Management in Germany. His international experience across diverse healthcare markets enriches his perspective on leadership and innovation in pharmaceutical practices.

As Knoa Pharma moves forward, it understands the critical nature of adapting to an ever-evolving health landscape, particularly in the ongoing fight against the opioid crisis. With Goettler at the helm, the company looks forward to exploring new avenues for growth and innovation, ensuring that the health of the community remains at the forefront of their mission. For more information about Knoa Pharma and their initiatives focused on opioid crisis intervention, visit Knoa Pharma's official website.